Therapeutic Goods Amendment Regulations 2003 (No. 4) (Cth)
Therapeutic Goods Amendment Regulations 2003 (No. 4) 1
Statutory Rules 2003 No. 258 2
I, PHILIP MICHAEL JEFFERY, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following Regulations under the
Therapeutic Goods Act 1989 .Dated 9 October 2003
P. M. JEFFERY
Governor-General
By His Excellency’s Command
TRISH WORTH
Parliamentary Secretary to the Minister for Health and Ageing
These Regulations are the
Therapeutic Goods Amendment Regulations 2003 (No. 4) .
These Regulations commence as follows:
(a) on gazettal — regulations 1 to 3 and Schedule 1;
(b) on 1 October 2004 — Schedule 2.
Schedules 1 and 2 amend the
Therapeutic Goods Regulations 1990 .
(regulation 3)
omit (except section 31A and sections 31C to 31F).
insert (except sections 30EA, 31A and 31C to 31F).
omit (except section 31A and sections 31C to 31F)
insert (except sections 30EA, 31A and 31C to 31F)
omit , exportation
substitute
(1) For the purposes of paragraph 19 (6) (a) of the Act, in relation to medicines, medical practitioners engaged in clinical practice in or outside a hospital are a prescribed class of medical practitioners.
(1A) For the purposes of subsection 19 (6) of the Act, in relation to medicines, paragraph 19 (6) (aa) does not apply to a medical practitioner engaged in clinical practice outside a hospital if the medical practitioner:
(a) has demonstrated that, in relation to the proposed supply of the medicines, the medical practitioner does not have access to an ethics committee that could approve the supply; and
(b) has received an endorsement, from a specialist college with established expertise relevant to the use of the medicines, to supply the medicines.
insert
15A Conditions of registration of therapeutic goods
(1) For the purposes of paragraph 28 (5) (e) of the Act, a person to whom the registration of a therapeutic good specified in Part 1 of Schedule 10 relates must comply with the reporting requirements set out in the document entitled ‘Australian Guideline For Pharmacovigilance Responsibilities Of Sponsors Of Registered Medicines Regulated By Drug Safety And Evaluation Branch’ published by the Therapeutic Goods Administration, as in force from time to time.
(2) For the purposes of subregulation (1), a reference to a registered medicine or a registered medicinal product in the document mentioned in that subregulation is taken to be a reference to a therapeutic good.
substitute
(iv) the Direct Selling Association of Australia Inc;
omit
insert
(ca) Medicines Australia; and
omit the Federation of Australian Radio Broadcasters;
insert Commercial Radio Australia Limited;
omit The Australia New Zealand Food Authority
insert Food Standards Australia New Zealand
substitute
(i) government regulation;
(j) consumer representation.
insert
6A | Australian College of Acupuncturists Ltd |
insert
26AA | The Australian Association of Homotoxicology Incorporated |
insert
26BA | The Homeopathic Medicine Association Inc. |
after Ammonium iron (III) citrate
insert Borax
Borax pentahydrate
Boric acid
after Magnesium phosphate
insert Magnesium phosphate dibasic trihydrate
after Manganese (II) sulfate
insert Molybdenum trioxide
after Sodium glycerophosphate
insert Sodium perborate
insert
5A |
|
[ 20 ] Schedule 4, Part 4, Division 2, after item 51
insert
52 | the preparation only contains aqueous extracts of the hyphae, dried to powder form |
omit Bioflavonoids (except quercetin)
after Calcium hydroxycitrate
insert Calcium sodium caseinate
after Chondroitin sulfate — shark
insert Citrus bioflavonoids extract
after Propolis
insert Quercetin
[ 25 ] Schedule 4, Part 5, Division 2, Subdivision 2, before item 1
insert
1A | Borax | 3 mg of boron |
1B | Borax pentahydrate | 3 mg of boron |
1C | Boric acid | 3 mg of boron |
[ 26 ] Schedule 4, Part 5, Division 2, Subdivision 2, after item 4
insert
4A | Molybdenum trioxide | 125 mg of molybdenum |
[ 27 ] Schedule 4, Part 5, Division 2, Subdivision 2, after item 5
insert
6 | Sodium perborate | 3 mg of boron |
[ 28 ] Schedule 4, Part 5, Division 3, after item 1B
insert
1C | Calcium sodium caseinate | Derived from cows milk |
omit the Australian Red Cross Blood Service
insert the holder of a licence to manufacture blood and blood components
(regulation 3)
omit For the purposes
insert
(1) For the purposes
insert
(2) For the purposes of paragraph 3 (5) (e) of the Act, the presentation of therapeutic goods is unacceptable if the name applied to the goods is not sufficiently distinctive to allow for the identification of the goods for the purposes of recovery.
1. These Regulations amend Statutory Rules 1990 No. 394, as amended by 1991 Nos. 84 and 485; 1992 Nos. 19, 89, 109, 332, 370 and 430; 1993 No. 141; 1994 Nos. 150, 222 and 364; 1995 Nos. 33, 111, 192, 208, 253, 320 and 328; 1996 Nos. 9, 25 (disallowed by the House of Representatives on 10 September 1996), 131, 200 and 208; 1997 Nos. 162, 398, 399, 400 and 401 (disallowed by the Senate on 31 March 1998); 1998 Nos. 227, 247 and 369; 1999 Nos. 62, 209 and 324; 2000 Nos. 29, 48, 70, 123, 124, 267 and 358; 2001 Nos. 159, 160, 252 and 343; 2002 Nos. 9, 84, 114, 143, 234, 315 and 345; 2003 Nos. 111, 151 and 257.
2. Notified in the
Commonwealth of Australia Gazette on 16 October 2003.
0
0
0